Search For "dcgi"
SEC recommends COVID-19 vaccine Corbevax for 12-18 year age group: Sources
Updated : 4 years ago IST
New Delhi [India], February 15 (ANI): The Drugs Controller General of India (DCGI)'s Subject Expert Committee (SEC) has recommended Emergency Use Authorization to Hyderabad-based pharmaceutical company Biological E's COVID-19 vaccine, Corbevax, for the age group 12 to 18 years subject to
Read More
DCGI grants emergency-use approval to single-dose Sputnik Light COVID-19 v
Updated : 4 years, 1 month ago IST
New Delhi [India], February 6 (ANI): The Drugs Controller General of India (DCGI) has granted emergency-use permission to the single-dose Sputnik Light COVID-19 vaccine, informed Union Health Minister Mansukh Mandaviya on Sunday.
Read More
Bharat Biotech gets DCGI's nod to conduct intranasal booster dose trials
Updated : 4 years, 1 month ago IST
New Delhi [India], January 28 (ANI): The Drugs Controller General of India (DCGI) on Friday granted permission to Bharat Biotech to conduct clinical trials of intranasal vaccine BBV154.
Read More
DCGI grants conditional market approval for Covaxin, Covishield
Updated : 4 years, 1 month ago IST
New Delhi [India], January 27 (ANI): The Drugs Controller General of India (DCGI) on Thursday granted conditional regular market approval for COVID-19 vaccines Covaxin and Covishield for restricted use in emergency situations in the adult population.
Read More
Regular market approval to Covishield, Covaxin expected soon after final p
Updated : 4 years, 1 month ago IST
New Delhi [India], January 26 (ANI): The regular market approval from Drugs Controller General of India (DCGI) to COVID-19 vaccine Covishield and Covaxin is expected soon, but only after price fixation which is still underway, official sources told ANI on Wednesday.
Read More
Deaths have been considerably reduced due to COVID-19 vaccination: ICMR
Updated : 4 years, 1 month ago IST
New Delhi [India], January 20 (ANI): Indian Council of Medical Research (ICMR) head Dr Balram Bhargava, in a health briefing, on Thursday asserted that deaths have been considerably reduced due to COVID-19 vaccinations in this third surge of the coronavirus infection.
Read More
SEC recommends regular market approval to Covaxin, Covishield for adults
Updated : 4 years, 1 month ago IST
New Delhi [India], January 19 (ANI): The Drugs Controller General of India's (DCGI) subject expert committee (SEC) has recommended the regular market approval to Serum Institute of India and Bharat Biotech for their COVID-19 vaccines Covaxin and Covishield with conditions for the adult po
Read More
SEC asks for more data to grant full market approval to Covaxin and Covish
Updated : 4 years, 1 month ago IST
New Delhi [India], January 14 (ANI): The Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) will continue thorough review of data submitted by the Serum Institute of India (SII) and Bharat Biotech for granting full market approval to Covaxin and Covishield, sources
Read More
DCGI's SEC to review applications of Bharat Biotech, SII for full market a
Updated : 4 years, 1 month ago IST
New Delhi [India], January 14 (ANI): Drugs Controller General of India (DCGI)'s Subject Expert Committee will review applications of Bharat Biotech and Serum Institute of India (SII) for full market approval to Covaxin and Covishield respectively on Friday, sources said.
Read More
COVID-19: Oral anti-viral drug Molnupiravir is not included in national ta
Updated : 4 years, 2 months ago IST
New Delhi [India], January 5 (ANI): Indian Council of Medical Research (ICMR) head Dr. Balram Bhargava on Wednesday stated that the oral anti-viral drug Molnupiravir capsules are not included in the national task force treatment for COVID-19 as it has side effects.
Read More
DCGI approves India-made RT-PCR kit to detect Omicron: Centre
Updated : 4 years, 2 months ago IST
New Delhi [India], January 5 (ANI): An RT-PCR test kit for detecting new coronavirus variant Omicron has been developed in India in partnership with Tata MD and the Indian Council of Medical Research (ICMR), said Dr Balram Bhargava, Director General of ICMR on Wednesday.
Read More
Bharat Biotech gets SEC approval for phase 3 clinical trials of COVID boos
Updated : 4 years, 2 months ago IST
New Delhi [India], January 5 (ANI): The Subject Experts Committee (SEC) of the Drug Controller General of India (DCGI) on Wednesday granted approval to Bharat Biotech for conducting intranasal phase 3 trials and heterologous trials for COVID-19 booster intranasal vaccine for those who hav
Read More